Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noopur Raje

Showing results (1-10 of 204) with videos related to

Pageof 21
Sort By:
Leukemia|November 30, 2019
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?Mattia D'Agostino, Noopur Raje
Current Opinion in Molecular Therapeutics|October 2, 2010
Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone lossNoopur Raje, Sonia Vallet
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|December 6, 2011
Bone anabolic agents for the treatment of multiple myelomaSonia Vallet, Noopur Raje
The Oncologist|April 16, 2011
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the futureSamantha Pozzi, Noopur Raje
The New England Journal of Medicine|September 18, 2010
Bisphosphonates and atypical femoral fracturesSamantha Pozzi, Noopur Raje
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2020
How We Approach Smoldering Multiple MyelomaNoopur Raje, Andrew J Yee
The New England Journal of Medicine|August 27, 2015
Monoclonal Antibodies in Multiple Myeloma Come of AgeNoopur Raje, Dan L Longo
Hematology. American Society of Hematology. Education Program|December 10, 2021
Minimal residual disease in multiple myeloma: why, when, whereAndrew J Yee, Noopur Raje
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2011
Advances in the biology and treatment of bone disease in multiple myelomaNoopur Raje, G David Roodman
The New England Journal of Medicine|March 8, 2002
Case 27-2001: Waldenstrom's macroglobulinemiaHarvey E Finkel, Noopur Raje
Pageof 21

Showing results (1-10 of 204) with videos related to

Sort By:
Pageof 21
Leukemia|November 30, 2019
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?Mattia D'Agostino, Noopur Raje
Current Opinion in Molecular Therapeutics|October 2, 2010
Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone lossNoopur Raje, Sonia Vallet
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|December 6, 2011
Bone anabolic agents for the treatment of multiple myelomaSonia Vallet, Noopur Raje
The Oncologist|April 16, 2011
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the futureSamantha Pozzi, Noopur Raje
The New England Journal of Medicine|September 18, 2010
Bisphosphonates and atypical femoral fracturesSamantha Pozzi, Noopur Raje
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2020
How We Approach Smoldering Multiple MyelomaNoopur Raje, Andrew J Yee
The New England Journal of Medicine|August 27, 2015
Monoclonal Antibodies in Multiple Myeloma Come of AgeNoopur Raje, Dan L Longo
Hematology. American Society of Hematology. Education Program|December 10, 2021
Minimal residual disease in multiple myeloma: why, when, whereAndrew J Yee, Noopur Raje
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2011
Advances in the biology and treatment of bone disease in multiple myelomaNoopur Raje, G David Roodman
The New England Journal of Medicine|March 8, 2002
Case 27-2001: Waldenstrom's macroglobulinemiaHarvey E Finkel, Noopur Raje
Pageof 21